11:06 AM EST, 12/04/2024 (MT Newswires) -- INmune Bio ( INMB ) said Wednesday it has entered into deal to use Vivo, a generative artificial intelligence-powered control tower produced by OmniScience, in undertaking its global phase 2 Alzheimer's disease clinical trial.

Vivo is designed specifically for centralizing and analyzing vast clinical data in real time, according to INmune. With insights becoming immediately available using Vivo, the company expects enhanced decision-making in the clinical trial.

Terms of the partnership weren't disclosed.

Shares of INmune Bio ( INMB ) were more than 3% lower in recent trading.

Price: 5.00, Change: -0.17, Percent Change: -3.29